FIELD: chemistry.
SUBSTANCE: in general formula
A represents optionally substituted aminocarbonyl group -N-C(O)-, in which amino group can be substituted and substituents can be selected from hydrogen, C1-C5alkyl, possibly substituted with C1-C3alkoxy, C3-C6cycloalkyl, 5-6-membered heteroaryl, in which heteroatoms are selected from oxygen or nitrogen; aryl, selected from phenyl, possibly substituted with hydroxy, C1-C5alkyl, C1-C5alkoxy, halogen, C1-C5acylamino group, or naphthyl; or amino group is selected from C3-C7heterocyclyl, containing 1-2 heteroatoms in cycle, selected from nitrogen, oxygen or sulphur, possibly substituted with hydroxy, C1-C3alkyl, benzyl, phenyl, which can be substituted with halogen, and said heterocyclyl can be condensed with benzene ring; acylamino group, in which acyl is selected from C1-C6alkylcarbonyl, where alkyl can be substituted with phenyl, substituted with phenyl, in which substituents are selected from C1-C5alkoxy; 5-membered heteroaryl with heteroatom, selected from atom of oxygen or sulphur; benzoyl, possibly substituted with C1-C5alkyl, C1-C5alkoxy, C1-C5alkylthio or halogen, methylenedioxy; heterocyclylcarbonyl, in which heterocyclyl is selected from 5-6-membered heterocyclyl, with 1-2 heteroatoms, selected from nitrogen, oxygen or sulphur, possibly condensed with benzene ring and possibly substituted with C1-C5alkyl, halogen; or ureido group, in which one of substituents of terminal amido group represents hydrogen, and the second substituent is selected from: C1-C3alkyl, substituted with phenyl, 5-membered saturated or aromatic heterocyclyl, in which heteroatoms are selected from oxygen or sulphur; C2-C6alkenyl; aryl, selected from phenyl, substituted with C1-C5alkyl, C1-C5alkoxy, ethylenedioxy, methylenedioxy, halogen, C1-C3alkylcarbonyl; 5-membered heterocyclyl, in which heteroatoms are selected from sulphur or oxygen atom, and possibly substituted with alkyloxycarbonyl group; B represents non-aromatic cyclic substituent, selected from C4-C6cycloalkyl; and has other values, given in the invention formula. Values R1a R1b R1c are given in the invention formula.
EFFECT: increased efficiency of application of compounds.
12 cl, 8 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CXCR7 ANTAGONISTS | 2013 |
|
RU2649004C2 |
| FIVE-MEMBERED HETEROCYCLIC PYRIDINE COMPOUNDS AND PREPARATION METHOD AND USE THEREOF | 2014 |
|
RU2668074C2 |
| DERIVATIVES OF 8-METHOXY-[1,2,4]TRIAZOLO[1,5-a]PYRIDINE AND PHARMACEUTICAL PREPARATION BASED ON THEREOF | 2002 |
|
RU2297416C2 |
| METHOD OF TREATMENT OR PREVENTION OF PHYSIOLOGICAL AND/OR PATHOPHYSIOLOGICAL CONDITIONS MEDIATED BY GROWTH HORMONE SECRETION STIMULATING RECEPTORS, TRIAZOLE AND BASED PHARMACEUTICAL COMPOSITION | 2006 |
|
RU2415134C9 |
| PHENOXYMETHYL DERIVATIVES | 2016 |
|
RU2746481C1 |
| COMPOUNDS USEFUL AS TRPM8 MODULATORS | 2011 |
|
RU2608109C2 |
| AZADECALINS CONDENSED WITH HETEROARYLKETONES - GLUCOCORTICOID RECEPTOR MODULATORS | 2013 |
|
RU2639867C2 |
| 3-CARBOXY-4-AMINOQUINOLINE DERIVATES, USEFUL AS SWEET TASTE MODIFIERS | 2011 |
|
RU2605549C2 |
| PPAR-SUPPORTING COMPOUNDS FOR TREATING METABOLIC DISEASES | 2014 |
|
RU2687490C2 |
| PRODRUG OF TRIAZOLONE COMPOUND | 2011 |
|
RU2581369C2 |
